Back to trial
Eligibility Pre-Screening
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
This is a simplified pre-screening tool. Your answers help estimate whether you might qualify, but only the research team can confirm your eligibility. This is not medical advice.
Question 1 of 50%